Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

March 02, 2023

Anthony Mato, MD, MSCE, discusses recent data on the emerging class of noncovalent BTK inhibitors in chronic lymphocytic leukemia and their potential advantage over currently approved covalent BTK inhibitors.

March 02, 2023

Jonathan E. Rosenberg, MD, discusses key safety and efficacy data from the EV-103 trial supporting supplemental biologics license applications seeking FDA approval of enfortumab vedotin plus pembrolizumab in patients with advanced urothelial cancer.

February 27, 2023

Sergio A. Giralt, MD, discusses the investigation of idecabtagene vicleucel vs standard-of-care regimens in patients with triple-class exposed relapsed/refractory multiple myeloma in the phase 3 Karmma-3 trial.

February 26, 2023

Lenvatinib in combination with pembrolizumab led to deep and durable tumor responses in patients with previously treated advanced endometrial carcinoma.

February 24, 2023

James Harding, MD, discusses future directions in the treatment of patients with advanced biliary tract cancer.

February 23, 2023

James Harding, MD, discusses key trials contributing to the evolution of frontline chemoimmunotherapy approaches in advanced biliary tract cancer.

February 20, 2023

Tiffany A. Traina, MD, discusses the significance of the FDA approval of sacituzumab govitecan for patients with metastatic hormone receptor-positive, HER2-negative breast cancer and expanded on the data from TROPiCS-02 that supported the approval.

February 17, 2023

Because of an economic burden on the healthcare system occurring through the per-patient cost of allogeneic hematopoietic cell transplant, novel treatments to replace transplant and prevent graft-vs-host disease are necessary.

February 13, 2023

James Harding, MD, highlighted current and emerging areas of research in biliary tract cancer, including key contributions from TOPAZ-1 and the phase 3 SWOG 1815 trial, the development of immunotherapy and chemotherapy combinations, and continued efforts to utilize personalized medicine in clinical practice.

February 02, 2023

For Kevin Kalinsky, MD, MS, director of breast medical oncology at the Winship Cancer Institute of Emory University in Atlanta, Georgia, his work on the RxPONDER trial serves as one of a few accomplishments for which he is grateful that have impacted clinical care.

January 25, 2023

Sergio A. Giralt, MD, discusses long-term outcomes with hematopoietic stem cell transplant in multiple myeloma

January 22, 2023

IK-175 was found to be well tolerated in patients with advanced solid tumors and to elicit responses in those with urothelial cancer when used alone or in combination with nivolumab, according to initial data from an ongoing phase 1a/b study.

January 21, 2023

Treatment with or without bevacizumab added to atezolizumab plus cisplatin/gemcitabine demonstrated a modest clinical benefit for patients with advanced biliary tract cancer.

January 20, 2023

The combination of nivolumab (Opdivo) and chemotherapy continued to provide a clinically meaningful long-term survival benefit and deeper responses than chemotherapy alone in previously untreated patients with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma, according to 3-year follow-up data from the phase 3 CheckMate-649 trial.

January 13, 2023

Gopa Iyer, MD, explained the rarity of TSC1 and TSC2 mutations in GU cancers, discussed the rationale and design of PRECISION 1, and emphasized the important role next-generation sequencing plays when determining the most effective targeted therapies for patients with GU cancers and other tumor types.

December 20, 2022

Melissa A. Lumish, MD, discusses emerging treatment strategies that could lead to more individualized treatment plans for patients with rectal cancer.

December 19, 2022

Raajit K. Rampal, MD, PhD, discusses the importance of clinical trial enrollment in patients with myelofibrosis.

December 17, 2022

Nour Abuhadra, MD, discusses what the data from DESTINY-Breast04 means for trastuzumab deruxtecan in the triple-negative breast cancer space and future areas of research for antibody-drug conjugates in this disease.

December 15, 2022

Anthony Mato, MD, MSCE, discusses the relapsed refractory setting compared with the frontline setting and promising agents such as pirtobrutinib and zanubrutinib.

December 11, 2022

The non-covalent BTK inhibitor pirtobrutinib showed high levels of response in heavily pretreated patients with Waldenström macroglobulinemia, regardless of prior treatment with a covalent BTK inhibitor.